Management of Intestinal Tuberculosis

Initial Treatment Regimen

The American Thoracic Society recommends initiating standard four-drug anti-tuberculous therapy immediately with isoniazid, rifampin, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for at least 4 additional months, for a minimum total duration of 6 months 1
The intensive phase (first 2 months) should include isoniazid 10-15 mg/kg/day, rifampin 10-20 mg/kg/day, pyrazinamide 15-30 mg/kg/day, and ethambutol 15-20 mg/kg/day 1
The continuation phase (months 3-6) should include isoniazid 10-15 mg/kg/day and rifampin 10-20 mg/kg/day 1

Baseline assessments before treatment should include visual acuity testing by Snellen chart, liver function tests, renal function, complete blood count, hepatitis B and C serologies, and HIV testing 2
Ongoing monitoring should include monthly visual acuity and color discrimination testing while on ethambutol, and liver function tests weekly for 2 weeks, then biweekly for the first 2 months if chronic liver disease is present 2

The American Thoracic Society recommends stopping all hepatotoxic drugs immediately if AST/ALT rises to ≥5 times the upper limit of normal without symptoms, or if AST/ALT ≥3 times the upper limit of normal with hepatitis symptoms 2
A bridge regimen with streptomycin and ethambutol should be used while the liver recovers 5

The American Thoracic Society recommends that all pediatric patients receive directly observed therapy (DOT) 6
Parents should not be relied upon to supervise DOT, and this is particularly important in adolescents where adherence may be challenging 6

The American Thoracic Society recommends considering extended therapy (up to 9 months) if there is a slow clinical response, persistent symptoms, or extensive disease 1